Zymeworks Inc. (ZYME) Stock Price

ZYMEStock

$25.03+34.93%52W

Market Cap$1.80B

P/E—

PEG Ratio—

Div yield—

Beta1.33

ZYME Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.13%

Price vs S&P 500 (4W)-5.31%

VGM Score43.17

Book Value / Share (Quarterly)$1.12

P/TBV (Annual)7.43x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-36.43%

Cash Flow / Share (Quarterly)$-1.68

Price vs S&P 500 (YTD)-16.86%

Net Profit Margin (TTM)-404.00%

EPS (TTM)$-2.01

10-Day Avg Trading Volume1.32M

EPS Excl Extra (TTM)$-2.01

Revenue Growth (5Y)22.13%

EPS (Annual)$-1.08

ROI (Annual)-30.22%

Net Profit Margin (5Y Avg)-231.32%

Cash / Share (Quarterly)$3.76

Revenue Growth QoQ (YoY)-90.58%

ROA (Last FY)-23.41%

Revenue Growth TTM (YoY)-61.23%

EBITD / Share (TTM)$-2.03

ROE (5Y Avg)-30.36%

Operating Margin (TTM)-418.99%

Cash Flow / Share (Annual)$-0.47

P/B Ratio24.75x

P/B Ratio (Quarterly)23.28x

Net Income / Employee (Annual)$-307,300

EV / Revenue (TTM)55.55x

Net Interest Coverage (TTM)-96.25x

ROA (TTM)-37.06%

EV / EBITDA (TTM)9.74x

EPS Incl Extra (Annual)$-1.08

Current Ratio (Annual)5.88x

Quick Ratio (Quarterly)5.86x

3-Month Avg Trading Volume0.74M

52-Week Price Return34.93%

EV / Free Cash Flow (Annual)0.77x

Revenue / Employee (TTM)$140,600

Tangible BV / Share (Quarterly)$1.10

P/S Ratio (Annual)18.77x

Asset Turnover (Annual)0.31x

52-Week High$31.34

Operating Margin (5Y Avg)-244.90%

EPS Excl Extra (Annual)$-1.08

CapEx CAGR (5Y)-17.89%

Tangible BV CAGR (5Y)-7.14%

26-Week Price Return-7.23%

Quick Ratio (Annual)5.52x

13-Week Price Return3.47%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.32x

Enterprise Value$2.06B

Revenue / Share Growth (5Y)12.68%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)-16.71%

Revenue / Employee (Annual)$401,400

Pretax Margin (Annual)-75.26%

Cash / Share (Annual)$3.04

3-Month Return Std Dev46.72%

Net Income / Employee (TTM)$-568,200

ROE (Last FY)-30.22%

Net Interest Coverage (Annual)-12.69x

EPS Basic Excl Extra (Annual)$-1.08

P/FCF (TTM)177.79x

Receivables Turnover (TTM)8.67x

EV / Free Cash Flow (TTM)1.36x

Total Debt / Equity (Quarterly)3.14x

EPS Incl Extra (TTM)$-2.01

Receivables Turnover (Annual)3.51x

ROI (TTM)-45.05%

P/S Ratio (TTM)53.58x

Pretax Margin (5Y Avg)-229.54%

Revenue / Share (Annual)$1.41

Tangible BV / Share (Annual)$3.55

Forward P/E22.84x

Price vs S&P 500 (52W)19.40%

Year-to-Date Return-4.94%

5-Day Price Return-1.18%

EPS Normalized (Annual)$-1.08

ROA (5Y Avg)-21.12%

Net Profit Margin (Annual)-76.56%

Month-to-Date Return-5.51%

Cash Flow / Share (TTM)$3.17

EBITD / Share (Annual)$-1.18

Operating Margin (Annual)-87.34%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-30.35%

LT Debt / Equity (Quarterly)3.14x

EPS Basic Excl Extra (TTM)$-2.01

P/TBV (Quarterly)23.58x

P/B Ratio (Annual)7.39x

Pretax Margin (TTM)-407.76%

Book Value / Share (Annual)$3.57

Price vs S&P 500 (13W)0.79%

Beta1.33x

P/FCF (Annual)15.19x

Revenue / Share (TTM)$0.51

ROE (TTM)-72.07%

52-Week Low$16.00

vGradeD

gGradeD

mGradeB

vgmGradeC

ZYME Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.59	-$0.62	-4.79%(-$0.03)
Q1 2026	May 7, 2026	-$0.10	-$0.59	-484.33%(-$0.49)
Q4 2025	Mar 2, 2026	-$0.32	-$0.55	-70.62%(-$0.23)
Q3 2025	Nov 6, 2025	-$0.32	-$0.26	+17.83%(+$0.06)
Q2 2025	Aug 7, 2025	-$0.47	$0.03	+106.36%(+$0.50)

ZYME Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.28

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ZYMEZymeworks Inc.	D	D	B	53.6x	-61.2%	—	—	$25.03
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics using its proprietary drug development platform. Its lead candidate, zanidatamab, is a HER2-targeted bispecific antibody currently in Phase 1/2 and pivotal clinical trials for solid tumors expressing HER2. The company also maintains a preclinical pipeline in oncology and other therapeutic areas.

ZYME Next Earnings Report

Report dateNov 9, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$2.15

Revenue estimate$218.29M

Also reporting on Nov 9, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

TRLVTrulieve Cannabis Corp.Pharmaceutical Preparations
CCThe Chemours CompanyChemicals
RXRXRecursion Pharmaceuticals, Inc. Class A Common StockBiological Products
NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$16.00

High$31.34